Hybryte™ clinical results demonstrate continued improvement post-treatment

Significant efficacy against plaque lesions also demonstrated with hybryte™ princeton, n.j. , dec. 2, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that analysis of the post-treatment data from the open-label study (protocol hpn-ctcl-04) comparing hybryte™ (synthetic hypericin) to valchlor® (mechlorethamine) has demonstrated continued improvement in hybryte™ treated patients and their individual lesions even after stopping treatment.
SNGX Ratings Summary
SNGX Quant Ranking